Top 50 Ai For Computational Biology in Latin America

The startup develops personalized pharmaceutical technology that tailors medication regimens based on individual patient profiles, enhancing therapeutic efficacy and minimizing adverse effects. By utilizing advanced data analytics and pharmacogenomics, the company aims to improve patient outcomes and overall quality of life.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

Nintx Next Innovative Therapeutics utilizes proprietary technologies such as xGIbiomics, which simulates the human gastrointestinal system, and GAIApath, an AI-driven analytics platform, to identify and develop plant-based therapies targeting multifactorial diseases. By leveraging Brazil's rich biodiversity, Nintx aims to create multi-target therapies that modulate human biological systems and the microbiome, addressing the limitations of traditional single-target drug approaches.

Onc.AI develops an AI-powered clinical management platform that utilizes a comprehensive oncology real-world dataset, including diagnostic imaging and genomics, to enhance treatment decision-making for metastatic lung cancer patients undergoing PD-1 immunotherapy. The platform provides actionable insights that enable oncologists to improve patient outcomes by optimizing treatment strategies based on real-world evidence.

Onward Assist is a predictive analytics platform that utilizes AI-driven image analysis to enhance cancer diagnosis by identifying biomarkers and reducing reporting time by 30-40%. The platform addresses the lack of effective cancer scoring tools tailored for diverse populations, enabling pathologists to make more accurate treatment decisions efficiently.

Cache DNA is developing a wet operating system for the storage and retrieval of biomolecules, utilizing scalable nucleic acid storage techniques to preserve biological data indefinitely. This technology addresses the challenge of data loss by enabling the long-term retention of both digital and biological information without the need for deletion.

Precision Data provides a business intelligence platform that utilizes generative artificial intelligence to optimize access to over 8 billion lines of structured clinical data, enhancing real-world evidence studies in healthcare. The company addresses the challenge of data quality and accessibility, enabling healthcare organizations to make informed decisions based on accurate and comprehensive information.

metaBIX Biotech has developed a platform that utilizes hardware, biotechnology, and artificial intelligence to monitor airborne pathogens, providing early warnings of potential disease outbreaks in plants, animals, and humans. This technology enables clients to implement preventive measures at least two weeks before an outbreak occurs, enhancing safety and public health.

Elegen utilizes proprietary cell-free DNA synthesis technology to produce long, complex, linear DNA up to 7 kb with 99.999% accuracy, eliminating the need for cloning. This rapid synthesis, delivered in 6 to 8 business days, addresses the critical bottleneck in DNA supply for synthetic biology applications, significantly reducing project timelines and costs.

CellRep develops cell reprogramming strategies to enhance T cell functionality, increasing their therapeutic potential for cancer and chronic conditions. The company provides an end-to-end pipeline from target discovery to preclinical validation, enabling more effective cell therapies for patients.

The startup is developing a Clinical Digital Twin Platform that creates virtual replicas of patients using real-time health data and advanced modeling techniques. This platform enables healthcare providers to personalize treatment plans and improve patient outcomes by simulating various clinical scenarios.

Embryoxite develops an AI-powered platform that analyzes embryo metabolomic data, genetic profiles, and morphokinetic imaging to assess implantation potential in pre-implantation embryos. This technology addresses the high failure rate of embryo implantation in IVF procedures by providing objective, data-driven insights that enhance selection accuracy and improve pregnancy outcomes.

Celestial AI develops the Photonic Fabric™, an optical interconnect technology that enhances data transfer speeds and reduces latency in AI computing and memory infrastructure. This technology addresses the limitations of traditional interconnects by enabling high-bandwidth, low-latency connections essential for processing extensive AI workloads efficiently.

The startup develops an artificial intelligence-based respiratory health monitoring system that analyzes individual and population-level respiratory data to track disease progression and treatment outcomes. This technology enables healthcare providers to implement timely interventions for patients with respiratory illnesses, improving overall care quality.

This biotech startup produces highly pure enzymes using recombinant DNA repair technology derived from Antarctic extremophiles, enabling large-scale replication of active ingredients. Their offerings provide clinicians with effective alternatives for skin health and rejuvenation in the cosmetic and pharmaceutical industries.

This startup produces frozen meals using artificial intelligence and cellular agriculture to create environmentally friendly food options. Their ready-to-eat products, such as breaded chicken and veggie cutlets, provide customers with convenient, responsibly sourced meals that are easy to store.

Clear Labs is a biotechnology firm that utilizes a genomics system to enhance diagnostic accuracy in clinical and application sectors. The company addresses the complexity of traditional diagnostic processes by providing streamlined genomic analysis, enabling faster and more reliable results.

D-Matrix has developed Corsair, an AI inference platform that achieves 60,000 tokens per second with 1 ms latency for Llama3 8B models, significantly enhancing throughput and energy efficiency in datacenters. This technology addresses the high computational costs and energy consumption associated with large-scale AI inference, enabling organizations to scale their AI capabilities sustainably.

Huna develops an AI engine that analyzes routine blood test data to identify risk patterns for early cancer detection and other chronic diseases. This technology enables healthcare providers to classify patients by risk level, improving clinical decision-making and increasing the chances of successful treatment while reducing overall healthcare costs.

TAXON utilizes artificial intelligence and genomic analysis to enhance soil microbiome understanding, enabling farmers and biotech companies to optimize crop yields and reduce reliance on agrochemicals. By providing detailed insights into microbial diversity and functionality, TAXON helps clients make informed decisions that lead to sustainable agricultural practices and improved productivity.

Aptah Bio is developing RNA WiCo™ technology, which restores RNA integrity and ensures accurate protein synthesis by facilitating proper U1 snRNP assembly. This approach targets the underlying RNA dysfunctions associated with age-related diseases, including Alzheimer’s and various cancers, by correcting mRNA processing errors.

This biotechnology platform decodes microbiomes to identify and manage their potential in productive environments. By providing insights from microbiome data, the platform helps researchers make informed decisions to minimize environmental impact and enhance performance.

Arkangel AI is a no-code platform that transforms medical data into AI algorithms for early disease detection, enabling healthcare organizations to build and deploy tailored solutions efficiently. By streamlining processes such as patient triage and drug adverse effect prediction, Arkangel AI enhances healthcare outcomes while significantly reducing operational costs.

Rosebud Biosciences develops targeted therapies for rare genetic diseases in children by utilizing organoids that replicate specific genetic mutations, allowing for precise drug screening. This approach addresses the critical lack of approved treatments for 95% of rare diseases, significantly improving the potential for effective cures.

The startup develops a generative artificial intelligence-based medical record system that automates healthcare billing by accurately reading documents and performing billing calculations. This technology reduces errors and processing time, enabling clinics and laboratories to enhance the efficiency of their medical billing operations.

The startup is a learning platform that connects software developers to collaboratively create digital products through shared coding environments and version control systems. This approach addresses the challenge of fragmented development efforts by facilitating real-time collaboration and knowledge exchange among developers.

Aperture Therapeutics develops a drug discovery engine that utilizes extensive cell libraries representing genetic diversity to identify gene variants that confer protection against neurodegenerative diseases. By targeting specific RNA transcripts, the company aims to create therapies that can delay brain aging and improve outcomes for affected populations.

The startup develops preventive treatments that enhance the natural immunity of fish, utilizing immunostimulants to improve resistance against bacterial pathogens and diseases. This approach replaces antibiotics, leading to higher survival rates and growth in aquaculture while providing cost-effective and sustainable solutions for fish cultivators.

Terraflos utilizes synthetic biology and cellular agriculture to produce high-value bioactive compounds from plant genetic information and stem cells, minimizing environmental impact. The startup addresses the growing demand for sustainable health and wellness solutions by providing optimized active ingredients for the cosmetic, food, nutraceutical, and pharmaceutical industries.

Kinzbio develops precision antimicrobial therapies using bacteriophages to target and eliminate specific bacterial pathogens. Their AI-driven platform rapidly identifies and optimizes phages for personalized treatments, offering a highly specific alternative to traditional antibiotics.

Comsentimento develops an AI-driven platform for clinical data transformation and research, focusing on enhancing cancer treatment and facilitating access to clinical trials. The platform provides healthcare professionals with actionable insights and support for chronic disease management, improving patient care and treatment adherence.

Yeda Health utilizes artificial intelligence to provide personalized dietary and lifestyle recommendations based on individual responses to food and continuous glucose monitoring data. This approach addresses the challenge of managing blood glucose levels by recognizing that each person's metabolic response is unique, enabling tailored strategies for metabolic stability.

The startup has developed a clinical research platform that utilizes machine learning to target the biological processes of aging, facilitating the discovery of therapies for age-related diseases such as cardiovascular and neurodegenerative conditions. By enabling pharmaceutical companies to enhance medical treatments, the platform addresses the need for more effective interventions in aging-related health issues.

GenAI is a platform that utilizes natural language processing to analyze customer feedback and extract actionable insights. By transforming unstructured data into structured information, it enables businesses to understand customer sentiment and improve their products and services.

The startup develops an all-in-one AI platform that integrates knowledge engineering into large enterprises through data engineering, customized models, and content creation tools. This technology enables businesses to optimize operations and drive growth by effectively managing and utilizing their data resources.

The startup utilizes a bio-based technological platform that employs genetic engineering tools and microalgae to produce valuable proteins and compounds, such as hirudin, which is traditionally sourced from sponges. This approach provides a sustainable and cost-effective solution for companies seeking hard-to-find biochemical compounds.

CytoEM Innovations decodes the electromagnetic identity of various cell types to precisely control their growth and behavior through interferometry. This technology addresses the challenges of low cell yield and high production costs in bioprocesses, enhancing efficiency in pharmaceutical and agricultural applications.

The startup offers an AI-driven platform that connects businesses with suitable partners throughout their innovation journey. By leveraging machine learning algorithms, it enhances strategic collaboration, enabling companies to identify and engage with startups that align with their specific needs.

Begen is a platform that connects businesses with specialized AI developers, enabling efficient access to AI solutions while reducing development costs. It addresses the challenge of AI adoption by providing a controlled environment for companies to implement AI-driven innovations and streamline their operations.

The startup develops chip technology that integrates big data analytics and heterogeneous computing to enhance the functionality of the Internet of Things. This technology enables industries, such as automotive and healthcare, to incorporate artificial intelligence into their products and services, improving operational efficiency and decision-making capabilities.

Ai Bruna utilizes artificial intelligence to optimize production processes across various industries by predicting raw material characteristics and enhancing operational efficiency. The platform reduces production costs, energy usage, and waste while improving product quality and profitability through data-driven decision-making.

AIMedic utilizes artificial intelligence to integrate diverse medical data sources, enhancing diagnostic accuracy and treatment selection for healthcare professionals. The platform supports patient monitoring through an intelligent assistant, providing validated educational resources and vital health updates to improve patient outcomes.

Base Cientifica offers comprehensive molecular and cellular research services to accelerate preclinical development and personalized medicine. They specialize in biological assay validation, biobanking, and molecular diagnostic assay development using PCR and NGS. Their services also include preclinical efficacy and safety studies, 3D organoid cultivation, and AI-driven R&D optimization.

This startup provides biotechnology services focused on developing industrial yeast strains and optimizing fermentation processes through advanced yeast metabolism and genetics research. Their solutions enable the yeast and fermentation industries to produce environmentally friendly products using renewable resources, addressing the need for sustainable manufacturing practices.

Fauna provides personalized gut health solutions through its gut insight test and prebiotic supplements. The company offers a holistic approach to wellness by analyzing an individual's microbiome and recommending targeted interventions to address root health issues naturally.

SIENTIA™ is an AIOps platform that enables the seamless deployment of AI models in Operational Technology environments, transforming Proofs of Concept into production-ready solutions. By integrating industry data, SIENTIA™ accelerates AI scalability and operational efficiency for heavy-asset industries, delivering measurable results in under one second of inference time.

The startup operates a genomics platform that centralizes and integrates DNA data to provide precise diagnoses and personalized treatment plans through advanced data analysis and interpretation. By leveraging genomic information, the platform enables researchers to enhance health outcomes and preventive care strategies for individuals.

The startup has developed a molecular diagnostic platform that integrates advanced fluidics, engineering, and bioinformatics to create a user-friendly in vitro diagnostic system. This technology enables healthcare providers to deliver precise clinical genomic information to patients, enhancing accessibility to essential diagnostics for improved treatment outcomes.

The startup develops AI-powered applications that enhance decision-making by analyzing large datasets and providing actionable insights. This technology enables organizations to make data-driven choices more efficiently, reducing uncertainty and improving operational outcomes.

The startup develops gene therapies utilizing a biocompatible delivery system to facilitate targeted treatment of genetic diseases. This approach enhances the efficacy of therapeutic interventions, addressing the limitations of traditional treatment methods in the biotechnological market.